Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

James R O’Dell1
Stanley B Cohen2
J Carter Thorne3
Joel Kremer4

1Department of Rheumatology, Division of Rheumatology and Immunology, University of Nebraska Medical Center and the Omaha VA, Omaha, NE, USA; 2Department of Internal Medicine, Metroplex Clinical Research Center, University of Texas Southwestern Medical School, Dallas, TX, USA; 3Division of Rheumatology, University of Toronto, Southlake Regional Health Centre, Toronto, ON, Canada; 4The Center for Rheumatology, Albany Medical College, Albany, NY, USA

Correspondence: James R O’Dell
Division of Rheumatology and Immunology, University of Nebraska Medical Center, 983025 Nebraska Medical Center, Omaha, NE 68198-3025, USA
Tel +1 402 559 7288
Fax +1 402 559 6788
Email jrodell@unmc.edu

Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA.

Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort).

Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort).

Conclusion: MTX is underused in the treatment of RA in the USA.

Keywords: biologic, claims, methotrexate, tumor necrosis factor

Introduction

Methotrexate (MTX) is the anchor drug to treat rheumatoid arthritis (RA).1,2 Guidelines of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) recommend MTX as first-line therapy.1,2 The ACR guidelines recommend biologic agents (with a tumor necrosis factor inhibitor [TNFi] as the first choice) be added for patients whose disease activity remains moderate or high despite treatment with a synthetic disease-modifying antirheumatic drug (DMARD).2 EULAR recommendations also state that biologics (the first choice is a TNFi) be reserved for patients with insufficient responses to MTX or other synthetic DMARDs.1 Although these guidelines are generally accepted, some believe that initial use of a TNFi is clinically superior to and more cost-effective than initial use of MTX,3 and that biologics, but not synthetic DMARDs, reduce radiographic progression in patients with RA.4 Such statements are not supported by data and are contradicted by results of systematic reviews and meta-analyses of clinical literature.5,6

Surveys and claims analyses have produced conflicting results regarding the use of biologics as initial DMARD treatment in RA. A survey of physicians focused on treatment of newly diagnosed patients indicated that 6% would use a TNFi as initial DMARD treatment.7 In contrast, claims analyses covering the period from 2006 to 2009 indicated that 10–15% of patients with RA initiated DMARD treatment with a biologic agent.8,9

Many patients with RA do not continue MTX when treatment with a biologic is initiated.9 Treatment guidelines state that TNFi should be combined with MTX in patients with inadequate responses to MTX and/or other conventional DMARDs.1
However, a previous claims analysis suggests that this is not done in approximately 30% of patients. The objectives of the present study were to determine the rates of biologic use among patients with no prior exposure to MTX who initiated biologic therapy for RA in either 2009 or 2012 and to delineate the percentage of patients for whom MTX was combined with a biologic during initial treatment or when the patient was switched to a biologic.

**Materials and methods**

**Data source**

Data were extracted from Symphony Health Solutions Integrated Dataverse, which contains information from medical, hospital, and prescription health care claims for approximately 274 million USA patients. Patient-specific information was de-identified to comply with the Health Insurance Portability and Accountability Act and encrypted with unique identifiers for longitudinal tracking. Approval from an institutional review board was not required for this claims analysis, and no patient identification was linked to any of the data evaluated.

**Data extraction and study cohorts**

Patients diagnosed with RA (ICD-9 codes 714.0 and 714.30) and who were naïve to MTX treatment, defined by its absence from claims throughout a 1-year look-back period, were included.

Patients were grouped into 1 of 2 cohorts. The “2009 cohort” consisted of patients who initiated MTX or a biologic in 2009 and had at least 1 RA-related claim in each year of the study. The “2012 cohort” comprised patients who initiated MTX or a biologic in 2012 and had at least 1 RA-related claim in each subsequent year of the study. The latter cohort was used to compare prescribing patterns for patients diagnosed in 2009 with those for patients diagnosed in 2012. All patients were followed through the end of 2014, with tracking of all medical, hospital, and prescription claims.

**Coding**

The National Drug Codes and the Healthcare Common Procedure Coding System were used to identify MTX and biologic products (abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, and tocilizumab) from the claims database.

**Comorbidities**

Comorbidities and prescription treatments were identified using ICD-9 codes, Healthcare Common Procedure Coding System, and National Drug Codes. Comorbidities were determined by the presence of ICD-9 codes submitted at any time during the study period.

**Data analysis**

Means, medians, and standard deviations were calculated for each cohort and each variable of interest. Differences between groups were analyzed using independent t-tests for continuous measures and chi-square tests for categorical values. P values <0.05 were considered significant.

**Results**

**Subjects**

The study included 48,910 patients who initiated treatment with MTX or a biologic in 2009 and 107,636 who started treatment in 2012. The major reason for the large numeric difference is that 4 years of follow-up were required for the 2009 cohort but only 2 years for the 2012 cohort. Demographic and clinical characteristics are summarized in Table 1. The prevalences of diabetes, ischemic cardiovascular disease, and gastrointestinal disease were higher in the 2009 cohort.

**Initiation of treatment with a biologic agent**

A biologic agent was the initial treatment for 27.1% of patients in 2009 and for 35.6% of patients in 2012 (P<0.0001) (Figure 1A). The cohorts differed slightly in exposure to non-MTX DMARDs prior to biologic use (Table 1). A significantly higher percentage of patients in the 2012 cohort received a non-MTX DMARD before treatment with a biologic agent (25.4% vs 15.3%; P<0.0001). However, even when these patients were excluded from the analysis, the between-group difference in use of a biologic before MTX remained significant (24.0% vs 29.1%; P<0.0001).

**Use of MTX in addition to biologic treatment**

Among patients who started biologic treatment without prior MTX, 39.2% of this subset of the 2009 cohort and 38.4% of the 2012 cohort initiated therapy with MTX and a biologic concomitantly (P>0.05) (Figure 1B). Among patients initially treated with oral MTX who received a biologic subsequently, 74.1% of this subset of the 2009 cohort and only 45.4% of the 2012 cohort continued to receive MTX (P<0.0001) (Figure 1C). This change in treatment pattern did not relate to a difference between cohorts in anti-TNF treatment: 52.3% of patients in the 2009 cohort who switched from oral MTX to a biologic received adalimumab, certolizumab, golimumab, or infliximab, as did 50.2% of the 2012 cohort.
There was significantly increased use of SC MTX from 2009 to 2012. Of the 35,640 patients who initiated oral MTX in 2009, 20,041 (56.2%) were switched from it during the subsequent 5 years. Of these, 2,513 (12.5%) were switched to SC MTX. In the 2012 cohort, 69,327 patients started oral MTX, and 18,989 (27.4%) were switched from this treatment in the ensuing 2 years. Of these, 3,976 (20.9%) were switched to SC MTX.
Discussion

The data indicate that in the USA, a large percentage of patients with RA receive a biologic without prior treatment with MTX and that this approach is increasing. Additionally, for patients who start a biologic without prior MTX, clinicians are not uniformly prescribing concomitant MTX, and again, this practice is increasing, observed in only 45.4% of patients from the 2012 cohort vs 74.1% of the 2009 cohort. These trends are alarming with regard to optimal clinical and certainly economical care.

Compared with earlier claims analyses,9,10 the present study indicates that there may have been a 2- to 3-fold increase in the use of biologic DMARDs without prior MTX in patients with RA. The reasons for this are not clear; guidelines for the initial treatment of RA did not change substantially during the time these analyses were conducted.2,11,12 Concurrent use of MTX and a TNFi is viewed as the standard of care for patients with RA whose disease activity continues despite MTX treatment,13 and this is consistent with results indicating better clinical responses to TNFi plus MTX vs monotherapy.14 Our analysis indicated that this guidance is not followed by many clinicians and is consistent with other results indicating underuse of MTX among patients receiving biologics.9,15

While not the primary focus of the study and on a brighter note, our analysis indicated that between 2009 and 2012, significantly more patients who initially received oral MTX were switched to SC MTX. This change in treatment patterns is consistent with results indicating significant clinical improvements with SC MTX in patients who discontinued the oral drug because of intolerance or inadequate efficacy.16–18 Although the use of SC MTX, which has better bioavailability and is better tolerated than oral MTX, is still much less than optimal, it at least appears to be increasing.

An obvious strength of the study is the very large data set (274 million lives). Since this is a claims analysis, a significant limitation is that the reasons for change to or adding another therapy are not known. The analysis used a 1-year look-back period, and this demonstrated that 15% of patients in the 2009 cohort and 25% of those in the 2012 cohort had received a non-MTX DMARD prior to the first treatment with either MTX or a biologic. Exclusion of these patients from the analysis did not change the conclusion that significantly more patients initiated a biologic prior to MTX treatment in the 2012 cohort vs the 2009 group. However, given that the look-back period was only 1 year, it is possible that some patients received MTX prior to the beginning of this period. Finally, it is important to emphasize that these results apply only to practice in the USA. It would be very interesting to determine if the trends reported have occurred in other countries.

Conclusion

This claims analysis shows that many patients with RA receive a biologic agent without prior treatment with MTX or any other synthetic DMARD and that this approach to treatment increased from 2009 to 2012. MTX is also underused in patients receiving a biologic agent, either as their first DMARD or after exposure to oral MTX. This suggests that many patients with RA in the USA are not receiving the maximum benefit of MTX, the most-effective conventional DMARD. Findings from this analysis raise major concerns about the quality and value of care provided for patients with RA in the USA.

Acknowledgment

The authors acknowledge the support of Robert W Rhoades, PhD, in development of the manuscript.

Author contributions

All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

Disclosure

Dr O’Dell has been a consultant for Medac Pharma, Bristol-Meyers Squibb, Eli Lilly and Company, Crescendo Bioscience, Coherus BioSciences, and GlaxoSmithKline. Dr Cohen is the medical director of Metroplex Clinical Research Center, and the center has received clinical trial grants from AbbVie, Amgen, Ardea Biosciences, Astellas Pharma Global Development, AstraZeneca, Boehringer Ingelheim, Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Flexion, Genentech, GlaxoSmithKline, Hoffmann-La Roche Inc., Janssen, MedImmune, Merck, Novartis, Pfizer Inc., Procter & Gamble Pharmaceuticals, Regeneron Pharmaceuticals, Roche, Sanofi-Aventis, UCB, and Vertex Pharmaceuticals. He has been a consultant for Amgen Inc., Boehringer Ingelheim, Biogen Idec, Bristol-Myers Squibb, Celltrion, Centocor Ortho Biotech Inc., Crescendo Bioscience, Flexion, Genentech, Pfizer Inc., Roche, and Sandoz. Dr Thorne has participated in advisory boards for AbbVie, Amgen, Celgene, Sanofi Genzyme, Hospira,
Janssen, Eli Lilly and Company, Medexus, Medac Pharma, Merck, Novartis, and Pfizer. He has been a consultant for AbbVie, Centocor, Sanofi Genzyme, Hospira, Eli Lilly and Company, Medexus, Medac Pharma, and Pfizer. He has been a speaker for Medexus and Medac Pharma. He has received IIS funding from AbbVie, Amgen, and Pfizer, and RCT funding from AbbVie, Celgene, CaREBiodam, Novartis, and Pfizer. Dr Kremer has received research support from AbbVie, Eli Lilly and Company, Novartis, and Pfizer. He has served as a consultant for AbbVie, Bristol-Meyers Squibb, GlaxoSmithKline, Eli Lilly and Company, and Pfizer. He is employed by Corrona. The authors report no other conflicts of interest in this work.

References